Lotte Biologics (Korean: 롯데바이오로직스) is a South Korean biotechnology company headquartered in Seoul.

In May 2022, Lotte Group entered the bio industry in earnest by acquiring Bristol Myers Squibb's biopharmaceutical plant with a production capacity of 40,000L.

[1] In June, Lotte Biologics was established as a subsidiary of Lotte Corporation.

[2] In July 2023, construction began on the first biopharmaceutical plant in Songdo, Incheon, with the goal of completion in 2025 and operation in 2027.

[3] It is a project to build three factories with a production capacity of 120,000 L each by investing approximately 4.6 trillion won by 2030.